Research.Patient.info
Non-Small Cell Lung Cancer (NSCLC) research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
This early-stage study is testing a new drug, furmonertinib, for advanced lung cancer. It's for people whose cancer has specific genetic changes (EGFR or HER2 mutations) and has progressed after previous treatments. Researchers are looking at its safety and how well it works.
United States · Australia · Canada - active not recruitingPHASE3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
This study compares a new drug, furmonertinib, at two different strengths, with standard chemotherapy for patients in the UK who have advanced non-small cell lung cancer with a specific genetic change called an EGFR exon 20 insertion mutation. It aims to see which treatment is more effective and safe as a first treatment.
United States · Australia · Brazil